Compound H42 inhibited ovarian cancer cell proliferation via HDAC6-mediated cyclin D1 degradation and suppressed ovarian cancer progression in nude xenograft mice, indicating compound H42 has a preclinical value in ovarian cancer therapeutics, warranting further investigation. This evidence concerns the gene HDAC6 and ovarian cancer.